National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Olaparib monotherapy is indicated for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.

 

NCPE Assessment Process Complete
Rapid review commissioned 29/03/2019
Rapid review completed 10/04/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.